US Stock Insider Trading | CeriBell disclosed 6 insider transactions on March 4

K-LinePoet · 2026-03-28T16:32:18+00:00

CeriBell disclosed on March 4, 2026, that executive Woo Raymond engaged in insider trading on March 2, involving multiple transactions with a total of 6,615 shares bought and sold. CeriBell is a medical technology company focused on the diagnosis and management of neurological disorders, developing an AI-powered EEG platform.

K-LinePoet

2026-03-28 16:32:18

Abstract generation in progress

On March 4, 2026, CeriBell (CBLL) disclosed six transactions involving company insiders. Executive Woo Raymond bought 6,615 shares on March 2, 2026.

【Recent Insider Transactions】

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
March 4, 2026	Executive	Woo Raymond	March 2, 2026	Sell	6,615	18.25	120,700
March 4, 2026	Executive	Woo Raymond	March 2, 2026	Buy	9,640	4.70	45,300
March 4, 2026	Executive	Woo Raymond	March 2, 2026	Buy	1,553	18.26	28,400
March 4, 2026	Executive	Woo Raymond	March 2, 2026	Buy	1,472	2.24	3,297.28
February 25, 2026	Executive	Blumberg Scott	February 23, 2026	Sell	808	19.79	16,000
February 25, 2026	Executive	Manni Joseph S.	February 23, 2026	Sell	768	19.79	15,200
February 25, 2026	Executive	Woo Raymond	February 23, 2026	Sell	705	19.79	14,000
February 25, 2026	Director	Chao Xingjuan	February 23, 2026	Sell	2,084	19.79	41,200
February 25, 2026	Executive	Foehr David	February 23, 2026	Sell	569	19.79	11,300
February 25, 2026	Executive	Foehr David	February 24, 2026	Sell	781	19.98	15,600

【Company Information】

CeriBell, Inc. was incorporated in Delaware on August 29, 2014. They are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with severe neurological disorders. They developed the Ceribell system, a novel point-of-care electroencephalogram (“EEG”) platform specifically designed to meet the unmet needs of patients in acute care settings. The Ceribell system combines proprietary, highly portable, quickly deployable hardware with sophisticated artificial intelligence (“AI”)-driven algorithms to enable rapid diagnosis and continuous monitoring of patients with neurological disorders. The Ceribell system harnesses the power of artificial intelligence to make EEGs more accessible and to enable continuous monitoring, allowing clinicians to diagnose and manage patients at risk of seizures more quickly and accurately in acute care environments, thereby improving patient outcomes and economic benefits for hospitals and payers.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes